Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 6/2015

01-06-2015 | Spondyloarthritis (MA Khan, Section Editor)

Revisiting MHC Genes in Spondyloarthritis

Authors: Maxime Breban, Félicie Costantino, Claudine André, Gilles Chiocchia, Henri-Jean Garchon

Published in: Current Rheumatology Reports | Issue 6/2015

Login to get access

Abstract

Spondyloarthritis (SpA) refers to a variety of inflammatory rheumatic disorders with strong heritability. Shared genetic predisposition, as shown by familial aggregation, is largely attributable to the major histocompatibility complex (MHC) locus, which was estimated to account for approximately half of the whole disease heritability. The first predisposing allele identified more than 40 years ago is HLA-B27, which is a major gene predisposing to all forms of SpA. However, despite intensive research, its pathogenesis remains uncertain. Other MHC alleles belonging to the class I and class II regions have been identified to exert additional effect. Candidate-gene approaches and genome-wide studies have recently allowed identification of several new loci residing outside of the MHC region that are involved in the predisposition to SpA. Interestingly, some of those new genes, such as ERAP1, ERAP2, and NPEPPS, code for aminopeptidases that are involved in MHC class I presentation and were shown to interact with HLA-B27.
Literature
1.
Amor B, Feldmann JL, Delbarre F, Hors J, Beaujan MM, Dausset J. Letter: HL-A antigen W27–a genetic link between ankylosing spondylitis and Reiter’s syndrome? N Engl J Med. 1974;290(10):572.PubMed
2.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010;70(1):25–31.CrossRefPubMed
3.•
Costantino F, Talpin A, Said-Nahal R, Goldberg M, Henny J, Chiocchia G, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis. 2015;74(4):689–93. Important epidemiological study combining for the first time HLA-B27 typing to SpA prevalence, using the new ASAS classification criteria.CrossRefPubMed
4.
Strand V, Rao SA, Shillington AC, Cifaldi MA, Mcguire M, Ruderman EM. Prevalence of axial spondyloarthritis in United States rheumatology practices: assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis: ASAS criteria versus clinical diagnosis in axial SpA. Arthritis Care Res. 2013;65(8):1299–306.CrossRef
5.
Breban M, Said-Nahal R, Hugot J-P, Miceli-Richard C. Familial and genetic aspects of spondyloarthropathy. Rheum Dis Clin N Am. 2003;29(3):575–94.CrossRef
6.
Said-Nahal R, Miceli-Richard C, Berthelot JM, Duché A, Dernis-Labous E, Le Blévec G, et al. The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d’Etude Génétique des Spondylarthropathies. Arthritis Rheum. 2000;43(6):1356–65.CrossRefPubMed
7.
Said-Nahal R, Miceli-Richard C, D’Agostino MA, Dernis-Labous E, Berthelot JM, Duché A, et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum. 2001;45(6):478–84.CrossRefPubMed
8.•
Baeten D, Breban M, Lories R, Schett G, Sieper J. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65(1):12–20. Up to date review on SpA concept: reality and controversies.CrossRefPubMed
9.
Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40(10):1823–8.CrossRefPubMed
10.
Khan MA. Polymorphism of HLA-B27: 105 subtypes currently known. Curr Rheumatol Rep. 2013;15(10):362.CrossRefPubMed
11.••
Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45(7):730–8. The largest case-control genetic study ever performed in ankylosing spondylitis resulted in doubling the number of known associated loci.CrossRefPubMedCentralPubMed
12.
Breban M, Miceli-Richard C, Zinovieva E, Monnet D, Said-Nahal R. The genetics of spondyloarthropathies. Joint Bone Spine Rev Rhum. 2006;73(4):355–62.CrossRef
13.
Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum. 1977;20(4):909–12.CrossRefPubMed
14.
Porcher R, Said-Nahal R, D’Agostino M-A, Miceli-Richard C, Dougados M, Breban M. Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. Arthritis Rheum. 2005;53(2):263–71.CrossRefPubMed
15.
Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2000;59(11):883–6.CrossRefPubMedCentralPubMed
16.
Dernis E, Said-Nahal R, D’Agostino M-A, Aegerter P, Dougados M, Breban M. Recurrence of spondylarthropathy among first-degree relatives of patients: a systematic cross-sectional study. Ann Rheum Dis. 2009;68(4):502–7.CrossRefPubMed
17.
Miceli-Richard C. Significant linkage to spondyloarthropathy on 9q31-34. Hum Mol Genet. 2004;13(15):1641–8.CrossRefPubMed
18.
Caffrey MFP, James DCO. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973;242(5393):121.CrossRefPubMed
19.
Khan MA, Mathieu A, Sorrentino R, Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev. 2007;6(3):183–9.CrossRefPubMed
20.
de Castro JA L. HLA-B27 and ankylosing spondylitis: tales from China. Tissue Antigens. 2010;75(1):9–11.CrossRefPubMed
21.
Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 2011;14(4):369–74.CrossRefPubMed
22.
Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Greenwood BM, McMichael AJ. HLA class I typing by PCR: HLA-B27 and an African B27 subtype. Lancet. 1991;337(8742):640–2.CrossRefPubMed
23.
Kchir MM, Hamdi W, Laadhar L, Kochbati S, Kaffel D, Saadellaoui K, et al. HLA-B, DR and DQ antigens polymorphism in Tunisian patients with ankylosing spondylitis (a case–control study). Rheumatol Int. 2010;30(7):933–9.CrossRefPubMed
24.
Liu X, Hu L-H, Li Y-R, Chen F-H, Ning Y, Yao Q-F. The association of HLA-B*27 subtypes with ankylosing spondylitis in Wuhan population of China. Rheumatol Int. 2010;30(5):587–90.CrossRefPubMed
25.
Armas JB, Gonzalez S, Martinez-Borra J, Laranjeira F, Ribeiro E, Correia J, et al. Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Tissue Antigens. 1999;53(3):237–43.CrossRefPubMed
26.•
Díaz-Peña R, López-Vázquez A, López-Larrea C. Old and new HLA associations with ankylosing spondylitis: HLA associations with ankylosing spondylitis. Tissue Antigens. 2012;80(3):205–13.CrossRefPubMed
27.
Van Gaalen FA. Does HLA-B*2706 protect against ankylosing spondylitis? A meta-analysis: metanalysis of HLA-B*2706 in ankylosing spondylitis. Int J Rheum Dis. 2012;15(1):8–12.CrossRefPubMed
28.
Paladini F, Taccari E, Fiorillo MT, Cauli A, Passiu G, Mathieu A, et al. Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis Rheum. 2005;52(10):3319–21.CrossRefPubMed
29.
Siala M, Mahfoudh N, Gdoura R, Younes M, Fourati H, Kammoun A, et al. Distribution of HLA-B27 and its alleles in patients with reactive arthritis and with ankylosing spondylitis in Tunisia. Rheumatol Int. 2009;29(10):1193–6.CrossRefPubMed
30.
Ben Radhia K, Ayed-Jendoubi S, Sfar I, Ben Romdhane T, Makhlouf M, Gorgi Y, et al. Distribution of HLA-B*27 subtypes in Tunisians and their association with ankylosing spondylitis. Joint Bone Spine Rev Rhum. 2008;75(2):172–5.CrossRef
31.
Taurog JD. The mystery of HLA-B27: if it isn’t one thing, it’s another. Arthritis Rheum. 2007;56(8):2478–81.CrossRefPubMed
32.
Fiorillo MT, Cauli A, Carcassi C, Bitti PP, Vacca A, Passiu G, et al. Two distinctive HLA haplotypes harbor the B27 alleles negatively or positively associated with ankylosing spondylitis in Sardinia: implications for disease pathogenesis. Arthritis Rheum. 2003;48(5):1385–9.CrossRefPubMed
33.
Diyarbakir E, Eyerci N, Melikoglu M, Topcu A, Pirim I. HLA B27 subtype distribution among patients with ankylosing spondylitis in Eastern Turkey. Genet Test Mol Biomark. 2012;16(5):456–8.CrossRef
34.
Park S-H, Kim J, Kim S-G, Kim S-K, Chung WT, Choe J-Y. Human leucocyte antigen-B27 subtypes in Korean patients with ankylosing spondylitis: higher B*2705 in the patient group. Int J Rheum Dis. 2009;12(1):34–8.CrossRefPubMed
35.
Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today. 1990;11(4):137–42.CrossRefPubMed
36.
Infantes S, Lorente E, Barnea E, Beer I, Barriga A, Lasala F, et al. Natural HLA-B*2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondylarthropathy. J Biol Chem. 2013;288(15):10882–9.CrossRefPubMedCentralPubMed
37.
Schittenhelm RB, Sian TCCLK, Wilmann PG, Dudek NL, Purcell AW. Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. Arthritis Rheum Hoboken NJ. 2015;67(3):702–13.CrossRef
38.
Marcilla M. López de Castro JA. Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis. Tissue Antigens. 2008;71(6):495–506.CrossRefPubMed
39.
Breban M, Fernández-Sueiro JL, Richardson JA, Hadavand RR, Maika SD, Hammer RE, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol Baltim Md 1950. 1996;156(2):794–803.
40.
May E, Dorris ML, Satumtira N, Iqbal I, Rehman MI, Lightfoot E, et al. CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol Baltim Md 1950. 2003;170(2):1099–105.
41.
Taurog JD, Dorris ML, Satumtira N, Tran TM, Sharma R, Dressel R, et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum. 2009;60(7):1977–84.CrossRefPubMed
42.•
Van Gaalen FA, Verduijn W, Roelen DL, Bohringer S, Huizinga TWJ, van der Heijde DM, et al. Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Ann Rheum Dis. 2013;72(6):974–8. Important study of the epistatic interaction between HLA-B27 and HLA-B60 (HLA-B*40:01) with regard to SpA predisposition.
43.
Robinson WP, van der Linden SM, Khan MA, Rentsch HU, Cats A, Russell A, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum. 1989;32(9):1135–41.CrossRefPubMed
44.
Wei JCC, Tsai WC, Lin HS, Tsai CY, Chou CT. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheum Oxf Engl. 2004;43(7):839–42.CrossRef
45.
Díaz-Peña R, Ouédraogo DD, López-Vázquez A, Sawadogo SA, López-Larrea C. Ankylosing spondylitis in three sub-Saharan populations: HLA-B*27 and HLA-B*14 contribution. Tissue Antigens. 2012;80(1):14–5.CrossRefPubMed
46.
Merino E, Galocha B, Vázquez MN. López De Castro JA. Disparate folding and stability of the ankylosing spondylitis-associated HLA-B*1403 and B*2705 proteins. Arthritis Rheum. 2008;58(12):3693–704.CrossRefPubMed
47.
Martinez-Borra J, Gonzalez S, López-Vazquez A, Gelaz M, Armas JB, Kanga U, et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol. 2000;61(2):131–9.CrossRefPubMed
48.••
Zhou X, Wang J, Zou H, Ward MM, Weisman MH, Espitia MG, et al. MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2014;73(8):1552–7. Important genetic study showing an association between several MICA alleles and ankylosing spondylitis in two distinct populations.CrossRefPubMedCentralPubMed
49.
Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–8.CrossRefPubMed
50.
Cascino I, Paladini F, Belfiore F, Cauli A, Angelini C, Fiorillo MT, et al. Identification of previously unrecognized predisposing factors for ankylosing spondylitis from analysis of HLA–B27 extended haplotypes in Sardinia. Arthritis Rheum. 2007;56(8):2640–51.CrossRefPubMed
51.
Paladini F, Belfiore F, Cocco E, Carcassi C, Cauli A, Vacca A, et al. HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia. Arthritis Res Ther. 2009;11(6):R171.CrossRefPubMedCentralPubMed
52.
Said-Nahal R, Miceli-Richard C, Gautreau C, Tamouza R, Borot N, Porcher R, et al. The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. Ann Rheum Dis. 2002;61(3):201–6.CrossRefPubMedCentralPubMed
53.
Hwang M, Zhou X, Weisman MH, Ward MM, Wang J, Gensler LS, et al. Shared HLA class I and II alleles in susceptibility to ankylosing spondylitis among three ethnic groups. Arthritis Rheum. 2014;66(10, SI):S271.
54.
Díaz-Peña R, Aransay AM, Bruges-Armas J, López-Vázquez A, Rodríguez-Ezpeleta N, Mendibil I, et al. Fine mapping of a major histocompatibility complex in ankylosing spondylitis: association of the HLA-DPA1 and HLA-DPB1 regions. Arthritis Rheum. 2011;63(11):3305–12.CrossRefPubMed
55.•
Díaz-Peña R, Castro-Santos P, Aransay AM, Brüges-Armas J, Pimentel-Santos FM, López-Larrea C. Genetic study confirms association of HLA-DPA1(∗)01:03 subtype with ankylosing spondylitis in HLA-B27-positive populations. Hum Immunol. 2013;74(6):764–7. Important confirmatory study replicating an association of HLA-DPA gene with ankylosing spondylitis in Hispanic populations.CrossRefPubMed
56.
Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329–37.CrossRef
57.
Reveille JD, Sims A-M, Danoy P, Evans DM, Leo P, Pointon JJ, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42(2):123–7.CrossRefPubMedCentralPubMed
58.
Evans DM, Spencer CCA, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43(8):761–7.CrossRefPubMedCentralPubMed
59.
Kadi A, Izac B, Said-Nahal R, Leboime A, Van Praet L, de Vlam K, et al. Investigating the genetic association between ERAP1 and spondyloarthritis. Ann Rheum Dis. 2013;72(4):608–13.CrossRefPubMed
60.
Alvarez-Navarro C, de Castro JA L. ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases. Mol Immunol. 2014;57(1):12–21.CrossRefPubMed
61.
Costantino F, Talpin A, Evnouchidou I, Kadi A, Leboime A, Said-Nahal R, et al. ERAP1 gene expression is influenced by non-synonymous polymorphisms associated with predisposition to spondyloarthritis. Arthritis Rheum Hoboken NJ. 2015. doi:10.​1002/​art.​39072.
62.
Carter KW, Pluzhnikov A, Timms AE, Miceli-Richard C, Bourgain C, Wordsworth BP, et al. Combined analysis of three whole genome linkage scans for ankylosing spondylitis. Rheumatology. 2007;46(5):763–71.CrossRefPubMed
63.
Falco M, Moretta L, Moretta A, Bottino C. KIR and KIR ligand polymorphism: a new area for clinical applications? Tissue Antigens. 2013;82(6):363–73.CrossRefPubMed
64.
Díaz-Peña R, Vidal-Castiñeira JR, Mulero J, Sánchez A, Queiro R, López-Larrea C. Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis: KIR locus polymorphism in ankylosing spondylitis. Clin Exp Immunol. 2014. doi:10.​1111/​cei.​12568.
65.
García-Medel N, Sanz-Bravo A, Alvarez-Navarro C, Gómez-Molina P, Barnea E, Marcilla M, et al. Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to endoplasmic reticulum aminopeptidase 1 (ERAP1). Mol Cell Proteomics MCP. 2014;13(12):3367–80.CrossRef
66.
Seregin SS, Rastall DPW, Evnouchidou I, Aylsworth CF, Quiroga D, Kamal RP, et al. Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity. 2013;46(8):497–508.CrossRefPubMedCentralPubMed
67.
McHugh K, Bowness P. The link between HLA-B27 and SpA—new ideas on an old problem. Rheumatology. 2012;51(9):1529–39.CrossRefPubMed
68.
Payeli SK, Kollnberger S, Marroquin Belaunzaran O, Thiel M, McHugh K, Giles J, et al. Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis. Arthritis Rheum. 2012;64(10):3139–49.CrossRefPubMed
69.
Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Mol Immunol. 2014;57(1):44–51.CrossRefPubMed
70.
Neerinckx B, Carter S, Lories RJ. No evidence for a critical role of the unfolded protein response in synovium and blood of patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(3):629–30.CrossRefPubMed
71.
Ciccia F, Accardo-Palumbo A, Rizzo A, Guggino G, Raimondo S, Giardina A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis. 2014;73(8):1566–74.CrossRefPubMed
72.
Utriainen L, Firmin D, Wright P, Cerovic V, Breban M, McInnes I, et al. Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis. Arthritis Rheum. 2012;64(10):3199–209.CrossRefPubMedCentralPubMed
73.
Dhaenens M, Fert I, Glatigny S, Haerinck S, Poulain C, Donnadieu E, et al. Dendritic cells from spondylarthritis-prone HLA-B27-transgenic rats display altered cytoskeletal dynamics, class II major histocompatibility complex expression, and viability. Arthritis Rheum. 2009;60(9):2622–32.CrossRefPubMed
74.
Hacquard-Bouder C, Falgarone G, Bosquet A, Smaoui F, Monnet D, Ittah M, et al. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy. Arthritis Rheum. 2004;50(5):1624–35.CrossRefPubMed
75.
Hacquard-Bouder C, Chimenti M-S, Giquel B, Donnadieu E, Fert I, Schmitt A, et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27. Arthritis Rheum. 2007;56(5):1478–89.CrossRefPubMed
76.
Fert I, Glatigny S, Poulain C, Satumtira N, Dorris ML, Taurog JD, et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN beta2-microglobulin-transgenic rat lines. Arthritis Rheum. 2008;58(11):3425–9.CrossRefPubMed
77.
Talpin A, Costantino F, Bonilla N, Leboime A, Letourneur F, Jacques S, et al. Monocyte-derived dendritic cells from HLA-B27+ axial spondyloarthritis (SpA) patients display altered functional capacity and deregulated gene expression. Arthritis Res Ther. 2014;16(4):417.CrossRefPubMedCentralPubMed
78.•
Fert I, Cagnard N, Glatigny S, Letourneur F, Jacques S, Smith JA, et al. Reverse interferon signature is characteristic of antigen-presenting cells in human and rat spondyloarthritis. Arthritis Rheum Hoboken NJ. 2014;66(4):841–51. Interesting study showing that both HLA-B27 transgenic rat and SpA patient antigen-presenting cells share a striking « reverse » interferon signature.CrossRef
79.•
Glatigny S, Fert I, Blaton MA, Lories RJ, Araujo LM, Chiocchia G, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64(1):110–20. This study shows that expression of HLA-B27 in transgenic rat dendritic cells results in a biased activation of CD4+ T cells towards pro-inflammatory Th17 effector profile.
80.
Araujo LM, Fert I, Jouhault Q, Labroquère K, Andrieu M, Chiocchia G, et al. Increased production of interleukin-17 over interleukin-10 by Treg cells implicates inducible costimulator molecule in experimental spondyloarthritis: imbalanced production of IL-10 and IL-17 by Treg cells from HLA-B27-transgenic rats. Arthritis Rheum. 2014;66(9):2412–22.CrossRef
81.•
Jeanty C, Sourisce A, Noteuil A, Jah N, Wielgosik A, Fert I, et al. HLA-B27 subtype oligomerization and intracellular accumulation patterns correlate with predisposition to spondyloarthritis. Arthritis Rheum Hoboken NJ. 2014;66(8):2113–23. This study reports the intriguing observation that the intra-cellular behavior of SpA-associated HLA-B27 diverges from that of non-associated alleles by more persistent dimers and an accumulation in large saccules.CrossRef
82.
Ruuska M, Sahlberg AS, Colbert RA, Granfors K, Penttinen MA. Enhanced phosphorylation of STAT-1 is dependent on double-stranded RNA-dependent protein kinase signaling in HLA-B27-expressing U937 monocytic cells. Arthritis Rheum. 2012;64(3):772–7.CrossRefPubMedCentralPubMed
Metadata
Title
Revisiting MHC Genes in Spondyloarthritis
Authors
Maxime Breban
Félicie Costantino
Claudine André
Gilles Chiocchia
Henri-Jean Garchon
Publication date
01-06-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 6/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0516-1

Other articles of this Issue 6/2015

Current Rheumatology Reports 6/2015 Go to the issue

Orphan Diseases (B Manger, Section Editor)

Tumor-Induced Osteomalacia: an Up-to-Date Review

Orphan Diseases (B Manger, Section Editor)

Multicentric Reticulohistiocytosis: a Critical Review

Health Economics and Quality of Life (M Harrison, Section Editor)

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

Health Economics and Quality of Life (M Harrison, Section Editor)

How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda

Spondyloarthritis (MA Khan, Section Editor)

Looking Into the New ASAS Classification Criteria for Axial Spondyloarthritis Through the Other Side of the Glass
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits